Zevra Therapeutics Stock Price Prediction

ZVRA Stock   9.59  0.46  5.04%   
The RSI of Zevra Therapeutics' the stock price is about 63. This usually means that the stock is rather overbought by investors at this time. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling Zevra, making its price go up or down.

Oversold Vs Overbought

63

 
Oversold
 
Overbought
The successful prediction of Zevra Therapeutics' future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Zevra Therapeutics, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Zevra Therapeutics' stock price prediction:
EPS Estimate Next Quarter
(0.35)
EPS Estimate Current Year
(1.94)
EPS Estimate Next Year
(0.32)
Wall Street Target Price
20.1429
EPS Estimate Current Quarter
(0.42)
Using Zevra Therapeutics hype-based prediction, you can estimate the value of Zevra Therapeutics from the perspective of Zevra Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Zevra Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Zevra because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Zevra Therapeutics after-hype prediction price

    
  USD 9.65  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Zevra Therapeutics Basic Forecasting Models to cross-verify your projections.
For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.
Intrinsic
Valuation
LowRealHigh
8.1511.5314.91
Details
Naive
Forecast
LowNextHigh
6.419.8013.18
Details
8 Analysts
Consensus
LowTargetHigh
17.5219.2521.37
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.54-0.48-0.39
Details

Zevra Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of Zevra Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Zevra Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Zevra Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Zevra Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting Zevra Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Zevra Therapeutics' historical news coverage. Zevra Therapeutics' after-hype downside and upside margins for the prediction period are 6.27 and 13.03, respectively. We have considered Zevra Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
9.59
9.65
After-hype Price
13.03
Upside
Zevra Therapeutics is somewhat reliable at this time. Analysis and calculation of next after-hype price of Zevra Therapeutics is based on 3 months time horizon.

Zevra Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Zevra Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Zevra Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Zevra Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.50 
3.38
  0.06 
  0.04 
9 Events / Month
13 Events / Month
In about 9 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
9.59
9.65
0.63 
3,073  
Notes

Zevra Therapeutics Hype Timeline

Zevra Therapeutics is at this time traded for 9.59. The entity has historical hype elasticity of 0.06, and average elasticity to hype of competition of -0.04. Zevra is projected to increase in value after the next headline, with the price projected to jump to 9.65 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is projected to be 0.63%, whereas the daily expected return is at this time at 0.5%. The volatility of related hype on Zevra Therapeutics is about 4524.41%, with the expected price after the next announcement by competition of 9.55. The company reported the previous year's revenue of 27.46 M. Net Loss for the year was (46.05 M) with profit before overhead, payroll, taxes, and interest of 10.12 M. Given the investment horizon of 90 days the next projected press release will be in about 9 days.
Check out Zevra Therapeutics Basic Forecasting Models to cross-verify your projections.
For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.

Zevra Therapeutics Related Hype Analysis

Having access to credible news sources related to Zevra Therapeutics' direct competition is more important than ever and may enhance your ability to predict Zevra Therapeutics' future price movements. Getting to know how Zevra Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Zevra Therapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
RNAZTranscode Therapeutics 0.02 4 per month 6.58  0.08  22.00 (11.43) 68.80 
FBIOFortress Biotech(0.06)8 per month 0.00 (0.1) 7.43 (5.08) 26.13 
AKBAAkebia Ther(0.1)8 per month 2.65  0.08  5.19 (4.11) 26.21 
TRVNTrevena(0.51)7 per month 0.00 (0.07) 20.99 (15.37) 99.50 
RVPHReviva Pharmaceuticals Holdings(0.04)5 per month 5.88  0.07  10.71 (9.86) 38.61 
GLUEMonte Rosa Therapeutics(0.25)9 per month 3.86  0.08  10.11 (8.18) 102.66 
PMVPPmv Pharmaceuticals(0.1)3 per month 2.01 (0.01) 3.75 (3.64) 13.98 
PHVSPharvaris BV(0.23)5 per month 2.98  0.06  7.76 (6.02) 21.41 
TYRATyra Biosciences 0.87 9 per month 0.00 (0.09) 5.20 (6.06) 34.43 
MOLNMolecular Partners AG(0.10)5 per month 0.00 (0.03) 9.61 (8.53) 52.92 
STOKStoke Therapeutics(0.04)10 per month 0.00 (0.09) 4.68 (6.99) 21.35 
ANTXAN2 Therapeutics(0.02)11 per month 1.86  0.06  3.64 (3.42) 28.03 
PASGPassage Bio(0.02)8 per month 0.00 (0.08) 9.33 (9.88) 25.50 
FDMT4D Molecular Therapeutics 0.21 9 per month 0.00 (0.24) 5.15 (5.78) 25.71 
CCCCC4 Therapeutics(0.35)10 per month 0.00 (0.11) 9.57 (7.98) 23.66 
FHTXFoghorn Therapeutics(0.58)10 per month 4.43  0.01  8.50 (6.81) 34.64 
STTKShattuck Labs 0.03 8 per month 0.00 (0.17) 7.03 (9.82) 52.02 

Zevra Therapeutics Additional Predictive Modules

Most predictive techniques to examine Zevra price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Zevra using various technical indicators. When you analyze Zevra charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Zevra Therapeutics Predictive Indicators

The successful prediction of Zevra Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Zevra Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Zevra Therapeutics based on analysis of Zevra Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Zevra Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Zevra Therapeutics's related companies.
 2021 2022 2023 2024 (projected)
Graham Number5.268.217.146.78
Receivables Turnover18.751.461.581.5

Story Coverage note for Zevra Therapeutics

The number of cover stories for Zevra Therapeutics depends on current market conditions and Zevra Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Zevra Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Zevra Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Zevra Therapeutics Short Properties

Zevra Therapeutics' future price predictability will typically decrease when Zevra Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Zevra Therapeutics often depends not only on the future outlook of the potential Zevra Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Zevra Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding35.5 M
Cash And Short Term Investments43 M

Complementary Tools for Zevra Stock analysis

When running Zevra Therapeutics' price analysis, check to measure Zevra Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zevra Therapeutics is operating at the current time. Most of Zevra Therapeutics' value examination focuses on studying past and present price action to predict the probability of Zevra Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zevra Therapeutics' price. Additionally, you may evaluate how the addition of Zevra Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins